The global tyrosine kinase inhibitors market is expanding owing to high prevalence and increase in incidence of cancer across the globe. The global tyrosine kinase inhibitors market was valued at more than US$ 18.0 Bn in 2017 and is projected to surpass US$ 19.0 Bn by 2026, expanding at a negative compound annual growth rate (CAGR) during the forecast period. The global market is witnessing expansion at a relatively higher growth rate owing to increasing expenditure on health care and high prevalence and increase in incidence of cancer across the globe.
Cancer is the unregulated growth of body cells due to genetic mutations in its differentiation regulatory genes. Tyrosine kinases are enzymes that signal the cell differentiation cycle, mutation in their expression genes leads to their over expression, which results in uncontrolled proliferation of cells to form tumors. Tyrosine kinase inhibitors are small molecules that bind to the receptor site of the kinase enzyme available at cell surface. This binding blocks the phosphorylation by blocking adenosine tri-phosphate (ATP) biding to the receptor. Based on type of kinase receptors being targeted, tyrosine kinase inhibitors can be classified into BCR-ABL TKIs, EGFR TKIs, VEGFR TKIs, Janus Kinase Inhibitors, BTK inhibitors.
Tyrosine kinase inhibitors (TKIs) aid patients suffering from different cancer diseases. Tyrosine kinase inhibitors were accepted largely due to specificity and efficacy and the benefits these offer over chemotherapy and radiotherapy. High prevalence and incidence rates of cancer diseases such as chronic myeloid leukemia (CML), lung cancer, breast cancer, and renal cell cancer, and expanding indications of existing and pipeline on TKIs have expanded the indication areas of existing and pipeline on tyrosine kinase inhibitors in order to address various unmet needs and extend the product lifecycle. These factors, collectively, are projected to drive the global tyrosine kinase inhibitors market in the near future. Furthermore, rise in awareness about cancer diagnosis and treatment and surge in adoption in underdeveloped and developing markets are key factors that are estimated to fuel the tyrosine kinase inhibitors market in the near future.
The global tyrosine kinase inhibitors market has been broadly segmented based on product, application, distribution channel, and region. In terms of product, the global market has been classified into BCR-ABL tyrosine kinase inhibitor, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor (VEGFR) tyrosine kinase inhibitors, and other tyrosine kinase inhibitors. BCR-ABL tyrosine kinase inhibitors were one of the first approved TKIs for cancer treatment. Their wide acceptance and indications have contributed to their significant share in the global market. VEGFR tyrosine kinase inhibitors are projected to be a highly promising class of TKIs. Several companies have developed their VEGFR TKIs drugs with features of multi kinase receptor inhibition. These factors are likely to augment the segment by the end of 2026. In terms of application, lung cancer is the leading cause of cancer deaths in the world. TKIs such as EGFR, ALK, and HGFR have been in use for treating lung cancers. Increase in incidence of lung cancer is likely to propel the segment.
In terms of distribution channel, the global tyrosine kinase inhibitors market has been segregated into hospital pharmacies, independent pharmacies, and online pharmacies. The hospital pharmacies segment is projected to account for a prominent share of the market. International and regional pharmacy service providers are expanding their operations across the regions, this is attributed to strong infrastructure network for distribution, thereby contributing to the dominant share held by the independent pharmacies segment of the global tyrosine kinase inhibitors market. Consolidation among independent pharmacies and their expanding operations across regions are likely to propel the independent pharmacies segment in the global market. Increase in adoption of e-commerce and convenience offered by online pharmacies are expected to drive the adoption of online pharmacies in developed markets.
In terms of region, the global tyrosine kinase inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market; however, it is projected to gain market share by the end of 2026. The market in North America is primarily driven by the high cost of TKIs and high health care expenditure, which have contributed to the leading share held by North America. Furthermore, demand for advanced treatment options such as targeted therapies has contributed to the leading share held by the region. Recent patent expiry of several blockbuster TKIs has negatively impacted the market in North America. However, the introduction of new TKIs, such as JAK TKIs, multi-targeted TKIs, ALT TKIs, and others has compensated for the impact, which is projected to fuel the TKIs market in North America during the forecast period. The tyrosine kinase inhibitors market in Asia Pacific is projected to expand at a rapid pace during the forecast period. Rest of Asia Pacific countries dominated the tyrosine kinase inhibitors market in Asia Pacific, while the market in China and India is estimated to expand at a significant CAGR during the forecast period.
Companies such as Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Johnson & Johnson accounted for a major share of the global tyrosine kinase inhibitors market in 2017. In May 2018, Pfizer's XALKORI (crizotinib) received FDA breakthrough therapy designation in two new indications. This is expected to increase the company's therapy segment research in the near future. Other global players operating in the market include AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., , Eisai Co., Ltd., and Eurofarma Laboratórios S/A, who are focused on strategic acquisitions and collaborations with parallel companies in order to improve and strengthen their geographic presence in the international market.
Presently, commercially available tyrosine kinase inhibitors are indicated for treating non-small cell lung cancer, renal cell cancer, breast cancer, chronic myeloid leukemia, hepatocellular carcinoma, and breast cancer. These drugs are indicated as monotherapy or combination therapy, along with chemotherapy or as post-surgical resection remedy. However, tyrosine kinase inhibitors are not available for other cancer types such as neuroendocrine tumors.
According to the National Cancer Institute of the U.S., around 1,735,350 new cancer cases were diagnosed in the U.S. in 2018. Moreover, the U.S. had 15.5 million cancer survivors in 2016, which is projected to increase to 20.3 million by 2026.
Surge in Adoption in Underdeveloped and Developing Markets
Global tyrosine kinase inhibitors market has been segmented as given below:
|
By Product |
|
|
By Application |
|
|
By Distribution Channel |
|
|
By Geography |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Tyrosine Kinase Inhibitors Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.3.4. Key Trends
4.4. Global Tyrosine Kinase Inhibitors Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
5. Global Tyrosine Kinase Inhibitors Market Outlook
5.1. Key Brand / Product Analysis
5.2. Patent & Market Exclusivity Analysis
5.3. Overview of Approved Indications
5.4. Tyrosine Kinase Inhibitors - Clinical Trial Analysis
5.5. Recent Industry Developments
5.6. Pipeline Analysis
5.7. Key Mergers & Acquisitions
6. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
6.3.1. BCR-ABL Tyrosine Kinase Inhibitors
6.3.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
6.3.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
6.3.4. Other Tyrosine Kinase Inhibitors
6.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Product
7. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
7.3.1. Chronic Myeloid Leukemia (CML)
7.3.2. Lung Cancer
7.3.3. Breast Cancer
7.3.4. Renal Cell Cancer
7.3.5. Others
7.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Application
8. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
8.3.1. Hospital Pharmacies
8.3.2. Independent Pharmacies
8.3.3. Online Pharmacies
8.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Distribution Channel
9. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Tyrosine Kinase Inhibitors Market Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East &Africa
9.3. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Country/Region
10. North America Tyrosine Kinase Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
10.2.1. BCR-ABL Tyrosine Kinase Inhibitors
10.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
10.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
10.2.4. Other Tyrosine Kinase Inhibitors
10.3. North America Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
10.3.1. Chronic Myeloid Leukemia (CML)
10.3.2. Lung Cancer
10.3.3. Breast Cancer
10.3.4. Renal Cell Cancer
10.3.5. Others
10.4. North America Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Independent Pharmacies
10.4.3. Online Pharmacies
10.5. North America Tyrosine Kinase Inhibitors Market Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Tyrosine Kinase Inhibitors Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Europe Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
11.2.1. BCR-ABL Tyrosine Kinase Inhibitors
11.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
11.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
11.2.4. Other Tyrosine Kinase Inhibitors
11.3. Europe Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
11.3.1. Chronic Myeloid Leukemia (CML)
11.3.2. Lung Cancer
11.3.3. Breast Cancer
11.3.4. Renal Cell Cancer
11.3.5. Others
11.4. Europe Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Independent Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By Distribution Channel
11.6.4. By Country
12. Asia Pacific Tyrosine Kinase Inhibitors Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
12.2.1. BCR-ABL Tyrosine Kinase Inhibitors
12.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
12.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
12.2.4. Other Tyrosine Kinase Inhibitors
12.3. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
12.3.1. Chronic Myeloid Leukemia (CML)
12.3.2. Lung Cancer
12.3.3. Breast Cancer
12.3.4. Renal Cell Cancer
12.3.5. Others
12.4. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Independent Pharmacies
12.4.3. Online Pharmacies
12.5.Market Forecast, by Country, 2016–2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By Distribution Channel
12.6.4. By Country
13. Latin America Tyrosine Kinase Inhibitors Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
13.2.1. BCR-ABL Tyrosine Kinase Inhibitors
13.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
13.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
13.2.4. Other Tyrosine Kinase Inhibitors
13.3. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
13.3.1. Chronic Myeloid Leukemia (CML)
13.3.2. Lung Cancer
13.3.3. Breast Cancer
13.3.4. Renal Cell Cancer
13.3.5. Others
13.4. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Independent Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By Distribution Channel
13.6.4. By Country
14. Middle East Tyrosine Kinase Inhibitors Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
14.2.1. BCR-ABL Tyrosine Kinase Inhibitors
14.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
14.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
14.2.4. Other Tyrosine Kinase Inhibitors
14.3. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
14.3.1. Chronic Myeloid Leukemia (CML)
14.3.2. Lung Cancer
14.3.3. Breast Cancer
14.3.4. Renal Cell Cancer
14.3.5. Others
14.4. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital Pharmacies
14.4.2. Independent Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-regions, 2016–2026
14.5.1. UAE
14.5.2. Saudi Arabia
14.5.3. Rest of Middle East & Africa
14.6. Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By Distribution Channel
14.6.4. By Country
15. Africa Tyrosine Kinase Inhibitors Market Analysis and Forecast
15.1.Introduction
15.1.1. Key Findings
15.2. Africa Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
15.2.1. BCR-ABL Tyrosine Kinase Inhibitors
15.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
15.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
15.2.4. Other Tyrosine Kinase Inhibitors
15.3. Africa Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
15.3.1. Chronic Myeloid Leukemia (CML)
15.3.2. Lung Cancer
15.3.3. Breast Cancer
15.3.4. Renal Cell Cancer
15.3.5. Others
15.4. Africa Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
15.4.1. Hospital Pharmacies
15.4.2. Independent Pharmacies
15.4.3. Online Pharmacies
15.5. Africa Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-regions, 2016–2026
15.5.1. South Africa
15.5.2. Rest of Africa
15.6. Africa Tyrosine Kinase Inhibitors Market Attractiveness Analysis
15.6.1. By Product
15.6.2. By Application
15.6.3. By Distribution Channel
16. Competition Landscape
16.1.Market Player – Competition Matrix (By Tier and Size of companies)
16.2.Global Tyrosine Kinase Inhibitors Market Snapshot of Companies (2017)
16.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
16.3.1. AstraZeneca Plc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Pfizer, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Novartis AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. Bristol-Myers Squibb Company
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Bayer AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. Boehringer Ingelheim International GmbH
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.6.5. Financial
16.3.7. F. Hoffmann-La Roche Ltd.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Johnson & Johnson
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
16.3.9. Eisai Co., Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Strategic Overview
16.3.10. Eurofarma Laboratórios S/A
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Strategic Overview
List of Tables
Table 01: Global BCR-ABL Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 02: Global EGFR Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 03: Global VEGFR Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 04: Global Other Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 05: Patent & Market Exclusivity Overview, by Molecule (1/4)
Table 06: Patent & Market Exclusivity Overview, by Molecule (2/4)
Table 07: Patent & Market Exclusivity Overview, by Molecule (3/4)
Table 08: Patent & Market Exclusivity Overview, by Molecule (4/4)
Table 09: Overview of Indications Approved, by Molecule (1/8)
Table 10: Overview of Indications Approved, by Molecule (2/8)
Table 11: Overview of Indications Approved, by Molecule (3/8)
Table 12: Overview of Indications Approved, by Molecule (4/8)
Table 13: Overview of Indications Approved, by Molecule (5/8)
Table 14: Overview of Indications Approved, by Molecule (6/8)
Table 15: Overview of Indications Approved, by Molecule (7/8)
Table 16: Overview of Indications Approved, by Molecule (8/8)
Table 17: BCR-ABL Tyrosine Kinase Inhibitors Pipeline Analysis (1/2)
Table 18: BCR-ABL Tyrosine Kinase Inhibitors Pipeline Analysis (2/2)
Table 19: EGFR Tyrosine Kinase Inhibitors Pipeline Analysis
Table 20: VEGFR Tyrosine Kinase Inhibitors Pipeline Analysis (1/3)
Table 21: VEGFR Tyrosine Kinase Inhibitors Pipeline Analysis (2/3)
Table 22: VEGFR Tyrosine Kinase Inhibitors Pipeline Analysis (3/3)
Table 23: Multi-target Tyrosine Kinase Inhibitors Pipeline Analysis
Table 24: Bruton’s Tyrosine Kinase Inhibitors Pipeline Analysis (1/2)
Table 25: Bruton’s Tyrosine Kinase Inhibitors Pipeline Analysis (2/2)
Table 26: Aurora Tyrosine Kinase Inhibitors Pipeline Analysis
Table 27: Other Tyrosine Kinase Inhibitors Pipeline Analysis (1/3)
Table 28: Other Tyrosine Kinase Inhibitors Pipeline Analysis (2/3)
Table 29: Other Tyrosine Kinase Inhibitors Pipeline Analysis (3/3)
Table 30: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 31: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 32: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 33: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 34: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 35: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 36: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 37: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 38: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 39: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 40: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 41: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 42: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 43: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 44: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 45: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 46: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 47: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 48: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 49: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 50: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 51: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 52: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 53: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 54: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 55: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 56: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
List of Figures
Figure 01: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 02: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 03: Global Tyrosine Kinase Inhibitors Market Value Share, by Product Type (2017)
Figure 04: Global Tyrosine Kinase Inhibitors Market Value Share, by Application (2017)
Figure 05: Global Tyrosine Kinase Inhibitors Market Value Share, by Distribution Channel (2017)
Figure 06: Global Tyrosine Kinase Inhibitors Market Value Share, by Region (2017)
Figure 07: Clinical Trial Analysis by Phase
Figure 08: Clinical Trial Analysis by Status
Figure 09: Clinical Trial Analysis by Completion and Termination Rate
Figure 10: Clinical Trial Analysis by Region
Figure 11: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 12: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by BCR-ABL TKIs, 2016–2026
Figure 13: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by EGFR TKIs, 2016–2026
Figure 14: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by VEGFR TKIs, 2016–2026
Figure 15: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Other TKIs, 2016–2026
Figure 16: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 17: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 18: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by CML, 2016–2026
Figure 19: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lung Cancer, 2016–2026
Figure 20: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Renal Cell Cancer, 2016–2026
Figure 21: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2016–2026
Figure 22: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016–2026
Figure 23: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018–2026
Figure 24: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 25: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2016–2026
Figure 26: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Independent Pharmacies, 2016–2026
Figure 27: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016–2026
Figure 28: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 29: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Region/Country, 2017 and 2026
Figure 30: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Region/Country, 2018–2026
Figure 31: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 32: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 33: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 34: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 35: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018?2026
Figure 36: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 37: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018?2026
Figure 38: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country, 2017 and 2026
Figure 39: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country, 2018–2026
Figure 40: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 41: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 42: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 43: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 44: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018?2026
Figure 45: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 46: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018?2026
Figure 47: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 48: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 49: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 50: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 51: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 52: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 53: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018?2026
Figure 54: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 55: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018?2026
Figure 56: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 57: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 58: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 59: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 60: Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 61: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 62: Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018 -2026
Figure 63: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 64: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 65: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 66: Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 67: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 68: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 69: Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 70: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 71: Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018 -2026
Figure 72: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 73: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 - 2026
Figure 74: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 75: Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 76: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 77: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 78: Africa Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 79: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 80: Africa Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018?2026
Figure 81: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 82: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018?2026
Figure 83: Global Tyrosine Kinase Inhibitors Market Share, by Company, 2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Tyrosine Kinase Inhibitors Market
*86 figures and 60 tables includes